JHL Biotech

Eden Biologics, founded in 2012 and based in Hsinchu, Taiwan, is a pioneering company in the biopharmaceutical industry. The company specializes in the development and manufacturing of large molecule biological drugs, focusing on biosimilars—biological products that are highly similar to already approved reference products. Eden Biologics serves a global clientele, including both patients in need of affordable medication and other pharmaceutical companies requiring contract development and manufacturing organization (CDMO) services.

Operating in the biotechnology and pharmaceutical markets, Eden Biologics employs advanced engineering and process technologies to produce high-quality biologics. The company has successfully passed numerous regulatory audits and inspections, including those from the Taiwan FDA and EU Qualified Person (QP).

Eden Biologics' business model revolves around two primary revenue streams: the sale of biosimilar medicines and the provision of CDMO services. By offering affordable biosimilars, the company aims to improve global healthcare accessibility. Additionally, its CDMO services cater to both global and regional clients, providing end-to-end solutions from drug development to manufacturing.

The company is committed to continuous learning, open communication, and team building, fostering a culture of trust and quality. Eden Biologics' leadership team brings extensive experience in financial analysis, cost management, and strategic planning, ensuring the company's growth and sustainability.

Keywords: biosimilars, CDMO, biopharmaceuticals, biotechnology, drug development, manufacturing, regulatory compliance, global healthcare, affordable medication, advanced engineering.